Last updated 2026-07-26
- Raised $3M Seed round, Jul 2025
- Raised $1M Pre-Seed round, May 2024
Total raised
$4.0M
Last: Undisclosed Round 2025-08
Stage
Seed
Founded
2023
Headcount
5
HQ
Giv'at Shmuel, Israel
Sector
Health Tech & Life Sciences
About
Hopec Pharma is transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) with HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy. This genetically modified Uropathogenic E. coli triggers a targeted immune response, offering higher efficacy, fewer side effects, and a scalable, cost-effective alternative to current treatment with Bacillus Calmette-Guérin (BCG). The company holds an exclusive IP license from Yissum and Hadasit with patents granted in the U.S., Europe, and China.
Funding history · 2 rounds · $4.0M total
2025-07
Seed
$3.0M
2024-05
Pre-Seed
$1.0M
Headcount over time
From 3 (2024-01) to 6 (2025-12) · +3 (+100%) · 5 points · source: Finder history + radar grounding
Q&A
- What is Hopec Pharma's primary focus?
- Hopec Pharma is a clinical-stage biotech company developing HOPEC (UPEC-FimON), a first-in-class non-intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC).
- When was Hopec Pharma founded and by whom?
- Hopec Pharma was founded in February 2023 by Estee Rosen and Gadi Klarsfeld.
- What is the total amount of funding Hopec Pharma has raised to date?
- Hopec Pharma has raised a total of $4,000,000 in funding.
- When did Hopec Pharma secure its most recent funding round and from whom?
- In August 2025, Hopec Pharma secured a Seed round of $3,000,000, with Israel Innovation Authority participating.
- What key milestones did Hopec Pharma achieve in 2025?
- In 2025, Hopec Pharma produced its first GMP clinical batch (DOR-100), received Helsinki approval for Phase 1/a+b, signed clinical agreements with Hadassah and Sheba Medical Centers, launched clinical trials, and was awarded a grant from the Israel Innovation Authority.
- Does Hopec Pharma hold any patents for its technology?
- Yes, Hopec Pharma holds an exclusive IP license from Yissum and Hadasit with patents granted in the U.S., Europe, and China.
- How many employees does Hopec Pharma currently have?
- Hopec Pharma currently has 1-10 employees.
- Who are the co-founders of Hopec Pharma and what are their roles?
- Estee Rosen is the Co-Founder & CEO, and Gadi Klarsfeld is the Co-Founder & CTO of Hopec Pharma.
Team · 2
Estee Rosen
Founder · Co-Founder & CEO
Gadi Klarsfeld
Founder · Co-Founder & CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 PatentsVerified
Tags
drug-developmentclinical-trialstargeted-cancer-therapycancercancer-therapyoncologycancer-researchbiopharmaceuticalimmuno-theraphyhealthcarepharmaceuticalsbiotechnologylife-sciencesimmunotherapybacteria
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | hopec-pharma.com |
|---|---|
| linkedin.com/company/93256826 |
Identifiers & details
| Founded | 2023-2 |
|---|---|
| Employees (exact) | 5 |
Radar intelligence
Web history (Wayback)
| Domain | hopec-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516759495 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2023-02-01 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — other (1) |
| Registered address | התאנה 1 גבעת שמואל |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-01 | שינוי בתקנון |